The report provides a comprehensive analysis of the potential of Oncology Device and Solution industry in India. The report covers an overview and genesis of the industry, market size in terms of revenue.

Its market segmentations include By Type, By Region, By Clinical Application, By Application, By End Users, By Test Type; growth enablers and drivers; challenges and bottlenecks; trends driving adoption trends; regulatory framework; end-user analysis, industry analysis, competitive landscape including competition scenario and market shares of major players. The report concludes with future market projections of each market segmentation and analyst recommendation's.

Market Overview:

According to Report Ocean estimates India Oncology Devices and Solutions Market (Revenue) has grown at a CAGR of $% from FY'17-22 supported by heightened manufacturing innovation and growing disease awareness. The rising medical devices industry is benefiting the growth of the oncology devices market.

India faces a sizable cancer burden, which continues to grow exponentially and is expected to rise to ~ Mn in 2025.

There are around ~ NABL accredited labs in India, where North and South Region have the maximum number of NABL certified Labs.

Key Trends by Market Segment:

By Clinical Application: In India, amongst all prevalent cancers, the five most common types are breast cancer, lung cancer, oral cancer, stomach cancer and cervical cancer. In India, every four minutes a woman is diagnosed with breast cancer.

By Test Type: Laboratory Cancer Diagnostic Tests like Bloods tests, urinanalysis, tumor markers, etc. account for around ~% of the total oncology tests performed in India. Other tests include tests like genetic tests, biopsies, etc.

Competitive Landscape

Future Outlook

India Oncology Devices and Solutions Market (Revenue) is expected to grow at a CAGR of $% from FY'2022-2027 with the oncology devices and solutions market capacity to steadily expand, meeting the underserved and unserved demand

Longer-term investments in the public sector are expected to increase for the current private sector exclusive treatments